Covaxin gets WHO approval

• In a major development WHO's Technical Advisory Group which was scheduled to meet today to decide the fate of Covaxin, has finally granted Emergency Use Listing (EUL) status to the vaccine

• This would mean that all those who have taken Covaxin need to self-quarantine in other countries and hence ensure ease of traveling

• Further, this would allow the Made-in-India vaccine to be available for Global use

• the vaccine was also reviewed by WHO’s Strategic Advisory Group of Experts on Immunization (SAGE), and recommended use of this vaccine in two doses, with a dose interval of four weeks, in all age groups 18 and above

• WHO said that covaxin was found to be 78% effective against COVID-19 after the second dose. Further, it was extremely suitable for low and middle-income countries due to ease of storage